A first-in-human, three-period crossover, double-blind, randomised, phase I study of CK 2127107 in healthy male volunteers

Trial Profile

A first-in-human, three-period crossover, double-blind, randomised, phase I study of CK 2127107 in healthy male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs CK 2127107 (Primary)
  • Indications Muscular atrophy
  • Focus Adverse reactions; First in man
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 30 Nov 2017 According to a Cytokinetics media release, results from this and two other studies (profiles 700242741 and 700247918) are published in Muscle & Nerve Journal "CK-2127107 Amplifies Skeletal Muscle Response to Nerve Activation in Humans".
    • 19 Jun 2015 According to a Cytokinetics media release, results from this and two other studies (profiles 700242741 and 700247918) were presented at the 19th International SMA (Spinal Muscular Atrophy) Researcher Meeting held during the 2015 Annual SMA Conference.
    • 13 Oct 2014 Status changed from active, no longer recruiting to completed, according to a Cytokinetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top